Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Author index

Page Path
HOME > Browse > Author index
Search
Seok-Woo Hong  (Hong SW) 2 Articles
Basic Research
Article image
Glucagon-Like Peptide Receptor Agonist Inhibits Angiotensin II-Induced Proliferation and Migration in Vascular Smooth Muscle Cells and Ameliorates Phosphate-Induced Vascular Smooth Muscle Cells Calcification
Jinmi Lee, Seok-Woo Hong, Min-Jeong Kim, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee
Diabetes Metab J. 2024;48(1):83-96.   Published online January 3, 2024
DOI: https://doi.org/10.4093/dmj.2022.0363
  • 2,581 View
  • 206 Download
  • 1 Web of Science
  • 1 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Glucagon-like peptide-1 receptor agonist (GLP-1RA), which is a therapeutic agent for the treatment of type 2 diabetes mellitus, has a beneficial effect on the cardiovascular system.
Methods
To examine the protective effects of GLP-1RAs on proliferation and migration of vascular smooth muscle cells (VSMCs), A-10 cells exposed to angiotensin II (Ang II) were treated with either exendin-4, liraglutide, or dulaglutide. To examine the effects of GLP-1RAs on vascular calcification, cells exposed to high concentration of inorganic phosphate (Pi) were treated with exendin-4, liraglutide, or dulaglutide.
Results
Ang II increased proliferation and migration of VSMCs, gene expression levels of Ang II receptors AT1 and AT2, proliferation marker of proliferation Ki-67 (Mki-67), proliferating cell nuclear antigen (Pcna), and cyclin D1 (Ccnd1), and the protein expression levels of phospho-extracellular signal-regulated kinase (p-Erk), phospho-c-JUN N-terminal kinase (p-JNK), and phospho-phosphatidylinositol 3-kinase (p-Pi3k). Exendin-4, liraglutide, and dulaglutide significantly decreased the proliferation and migration of VSMCs, the gene expression levels of Pcna, and the protein expression levels of p-Erk and p-JNK in the Ang II-treated VSMCs. Erk inhibitor PD98059 and JNK inhibitor SP600125 decreased the protein expression levels of Pcna and Ccnd1 and proliferation of VSMCs. Inhibition of GLP-1R by siRNA reversed the reduction of the protein expression levels of p-Erk and p-JNK by exendin-4, liraglutide, and dulaglutide in the Ang II-treated VSMCs. Moreover, GLP-1 (9-36) amide also decreased the proliferation and migration of the Ang II-treated VSMCs. In addition, these GLP-1RAs decreased calcium deposition by inhibiting activating transcription factor 4 (Atf4) in Pi-treated VSMCs.
Conclusion
These data show that GLP-1RAs ameliorate aberrant proliferation and migration in VSMCs through both GLP-1Rdependent and independent pathways and inhibit Pi-induced vascular calcification.

Citations

Citations to this article as recorded by  
  • Incretin Hormone Secretion in Women with Polycystic Ovary Syndrome: Roles of Obesity, Insulin Sensitivity and Treatment with Metformin and GLP-1s
    Andrea Etrusco, Mislav Mikuš, Antonio D’Amato, Fabio Barra, Petar Planinić, Trpimir Goluža, Giovanni Buzzaccarini, Jelena Marušić, Mara Tešanović, Antonio Simone Laganà
    Biomedicines.2024; 12(3): 653.     CrossRef
GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
Jinmi Lee, Seok-Woo Hong, Eun-Jung Rhee, Won-Young Lee
Diabetes Metab J. 2012;36(4):262-267.   Published online August 20, 2012
DOI: https://doi.org/10.4093/dmj.2012.36.4.262
  • 5,914 View
  • 77 Download
  • 62 Crossref
AbstractAbstract PDFPubReader   

Non-alcoholic fatty liver disease (NAFLD), one of the most common liver diseases, is caused by the disruption of hepatic lipid homeostasis. It is associated with insulin resistance as seen in type 2 diabetes mellitus. Glucagon-like peptide-1 (GLP-1) is an incretin that increases insulin sensitivity and aids glucose metabolism. In recent in vivo and in vitro studies, GLP-1 presents a novel therapeutic approach against NAFLD by increasing fatty acid oxidation, decreasing lipogenesis, and improving hepatic glucose metabolism. In this report, we provide an overview of the role and mechanism of GLP-1 in relieving NAFLD.

Citations

Citations to this article as recorded by  
  • Hepatic function of glucagon-like peptide-1 and its based diabetes drugs
    Jia Nuo Feng, Tianru Jin
    Medical Review.2024;[Epub]     CrossRef
  • Non-alcoholic fatty liver disease in type 2 diabetes: Emerging evidence of benefit of peroxisome proliferator-activated receptors agonists and incretin-based therapies
    Subhodip Pramanik, Partha Pal, Sayantan Ray
    World Journal of Methodology.2024;[Epub]     CrossRef
  • Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence
    Salvatore Corrao, Chiara Pollicino, Dalila Maggio, Alessandra Torres, Christiano Argano
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Assessing the therapeutic potential of long-chain isomaltooligosaccharides in diabetic and hyperlipidemic rats
    Onrapak Reamtong, Rattiya Waeonukul, Pattaneeya Prangthip
    Diabetology & Metabolic Syndrome.2024;[Epub]     CrossRef
  • The intestine as an endocrine organ and the role of gut hormones in metabolic regulation
    Rula Bany Bakar, Frank Reimann, Fiona M. Gribble
    Nature Reviews Gastroenterology & Hepatology.2023; 20(12): 784.     CrossRef
  • GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
    Riccardo Nevola, Raffaella Epifani, Simona Imbriani, Giovanni Tortorella, Concetta Aprea, Raffaele Galiero, Luca Rinaldi, Raffaele Marfella, Ferdinando Carlo Sasso
    International Journal of Molecular Sciences.2023; 24(2): 1703.     CrossRef
  • From Non-Alcoholic Fatty Liver Disease to Liver Cancer: Microbiota and Inflammation as Key Players
    Avilene Rodríguez-Lara, Ascensión Rueda-Robles, María José Sáez-Lara, Julio Plaza-Diaz, Ana I. Álvarez-Mercado
    Pathogens.2023; 12(7): 940.     CrossRef
  • Investigating the Opposing Effect of Two Different Green Tea Supplements on Oxidative Stress, Mitochondrial Function and Cell Viability in HepG2 Cells
    Aparna Shil, Chris Davies, Lata Gautam, Justin Roberts, Havovi Chichger
    Journal of Dietary Supplements.2022; 19(4): 459.     CrossRef
  • Antiobesity therapeutics with complementary dual‐agonist activities at glucagon and glucagon‐like peptide 1 receptors
    Bong Gyu Park, Gyeong Min Kim, Hye‐Jin Lee, Jae Ha Ryu, Dong‐Hoon Kim, Jae‐Young Seong, Soojeong Kim, Zee‐Yong Park, Young‐Joon Kim, Jaemin Lee, Jae Il Kim
    Diabetes, Obesity and Metabolism.2022; 24(1): 50.     CrossRef
  • The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs—Therapeutic potential exploration in lung injury
    Juan Pang, Jia Nuo Feng, Wenhua Ling, Tianru Jin
    Acta Pharmaceutica Sinica B.2022; 12(11): 4040.     CrossRef
  • Deficiency of peroxisomal NUDT7 stimulates de novo lipogenesis in hepatocytes
    Jinsoo Song, In-Jeoung Baek, Sujeong Park, Jinjoo Oh, Deokha Kim, Kyung Song, Mi Kyung Kim, Hye Won Lee, Byoung Kuk Jang, Eun-Jung Jin
    iScience.2022; 25(10): 105135.     CrossRef
  • Gut–Liver Axis and Non-Alcoholic Fatty Liver Disease: A Vicious Circle of Dysfunctions Orchestrated by the Gut Microbiome
    Salvatore Pezzino, Maria Sofia, Gloria Faletra, Chiara Mazzone, Giorgia Litrico, Gaetano La Greca, Saverio Latteri
    Biology.2022; 11(11): 1622.     CrossRef
  • Efficacy and safety of semaglutide for weight management: evidence from the STEP program
    Anastassia Amaro, Danny Sugimoto, Sean Wharton
    Postgraduate Medicine.2022; 134(sup1): 5.     CrossRef
  • Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
    Joanna Michałowska, Ewa Miller-Kasprzak, Paweł Bogdański
    Nutrients.2021; 13(2): 351.     CrossRef
  • Insights into the Impact of Microbiota in the Treatment of NAFLD/NASH and Its Potential as a Biomarker for Prognosis and Diagnosis
    Julio Plaza-Díaz, Patricio Solis-Urra, Jerónimo Aragón-Vela, Fernando Rodríguez-Rodríguez, Jorge Olivares-Arancibia, Ana I. Álvarez-Mercado
    Biomedicines.2021; 9(2): 145.     CrossRef
  • A comprehensive review for gut microbes: technologies, interventions, metabolites and diseases
    Changlu Qi, Ping Wang, Tongze Fu, Minke Lu, Yiting Cai, Xu Chen, Liang Cheng
    Briefings in Functional Genomics.2021; 20(1): 42.     CrossRef
  • Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome
    Maka Siamashvili, Stephen N. Davis
    Expert Review of Clinical Pharmacology.2021; 14(9): 1081.     CrossRef
  • Mechanistic and physiological approaches of fecal microbiota transplantation in the management of NAFLD
    Manisha Gupta, Pawan Krishan, Amarjot Kaur, Sandeep Arora, Nirupma Trehanpati, Thakur Gurjeet Singh, Onkar Bedi
    Inflammation Research.2021; 70(7): 765.     CrossRef
  • Retrospective analysis (2009–2017) of factors associated with progression and regression of non-alcoholic fatty liver disease (Hepatic steatosis) in patients with type 2 diabetes seen at a tertiary diabetes centre in Southern India
    Nithyanantham Kamalraj, Madhanagopal Sathishkumar, Mani Arunvignesh, Viswanathan Baskar, Saravanan Jebarani, Anandakumar Amutha, Mohan Deepa, Coimbatore Subramanyam Shanthi Rani, Sundaramoorthy Chandru, Ranjit Unnikrishnan, Ranjit Mohan Anjana, Mardavada
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(5): 102261.     CrossRef
  • Gastrointestinal Hormones in Healthy Adults: Reliability of Repeated Assessments and Interrelations with Eating Habits and Physical Activity
    Silke M. Wortha, Katharina A. Wüsten, Veronica A. Witte, Nicole Bössel, Wolfram Keßler, Antje Vogelgesang, Agnes Flöel
    Nutrients.2021; 13(11): 3809.     CrossRef
  • Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytes
    Jingya Lyu, Hitomi Imachi, Kensaku Fukunaga, Seisuke Sato, Toshihiro Kobayashi, Tao Dong, Takanobu Saheki, Mari Matsumoto, Hisakazu Iwama, Huanxiang Zhang, Koji Murao
    Molecular Metabolism.2020; 34: 16.     CrossRef
  • Effects of synbiotic consumption on lipid profile: a systematic review and meta-analysis of randomized controlled clinical trials
    Amir Hadi, Ehsan Ghaedi, Saman Khalesi, Makan Pourmasoumi, Arman Arab
    European Journal of Nutrition.2020; 59(7): 2857.     CrossRef
  • Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review
    Xiaodan Lv, Yongqiang Dong, Lingling Hu, Feiyu Lu, Changyu Zhou, Shaoyou Qin
    Endocrinology, Diabetes & Metabolism.2020;[Epub]     CrossRef
  • Genetic engineering of novel super long-acting Exendin-4 chimeric protein for effective treatment of metabolic and cognitive complications of obesity
    Jong Youl Lee, Taehoon Park, Eunmi Hong, Reeju Amatya, Kyung-Ah Park, Young-Hoon Park, Kyoung Ah Min, Minki Jin, Sumi Lee, Seungmi Hwang, Gu Seob Roh, Meong Cheol Shin
    Biomaterials.2020; 257: 120250.     CrossRef
  • A look to the future in non‐alcoholic fatty liver disease: Are glucagon‐like peptide‐1 analogues or sodium‐glucose co‐transporter‐2 inhibitors the answer?
    Rebecca K. Vincent, David M. Williams, Marc Evans
    Diabetes, Obesity and Metabolism.2020; 22(12): 2227.     CrossRef
  • A systematic review and meta-analysis of probiotic consumption and metabolic status of athletes
    Atefeh As’Habi, Maryam Nazari, Hossein Hajianfar, Arman Arab, Zeinab Faghfoori
    International Journal of Food Properties.2020; 23(1): 941.     CrossRef
  • The Gut Barrier, Intestinal Microbiota, and Liver Disease: Molecular Mechanisms and Strategies to Manage
    Julio Plaza-Díaz, Patricio Solís-Urra, Fernando Rodríguez-Rodríguez, Jorge Olivares-Arancibia, Miguel Navarro-Oliveros, Francisco Abadía-Molina, Ana I. Álvarez-Mercado
    International Journal of Molecular Sciences.2020; 21(21): 8351.     CrossRef
  • Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides
    L. Kořínková, V. Pražienková, L. Černá, A. Karnošová, B. Železná, J. Kuneš, Lenka Maletínská
    Frontiers in Endocrinology.2020;[Epub]     CrossRef
  • Have a heart: failure to increase GLP-1 caused by heart failure increases the risk of diabetes
    Michael J. Ryan
    Clinical Science.2020; 134(23): 3119.     CrossRef
  • Unraveling the Role of Leptin in Liver Function and Its Relationship with Liver Diseases
    Maite Martínez-Uña, Yaiza López-Mancheño, Carlos Diéguez, Manuel A. Fernández-Rojo, Marta G. Novelle
    International Journal of Molecular Sciences.2020; 21(24): 9368.     CrossRef
  • The Role of GLP1 in Rat Steatotic and Non-Steatotic Liver Transplantation from Cardiocirculatory Death Donors
    Cindy G. Avalos-de León, Mónica B. Jiménez-Castro, María Eugenia Cornide-Petronio, Araní Casillas-Ramírez, Carmen Peralta
    Cells.2019; 8(12): 1599.     CrossRef
  • LRG ameliorates steatohepatitis by activating the AMPK/mTOR/SREBP1 signaling pathway in C57BL/6J mice fed a high‑fat diet
    Tao Hao, Hongying Chen, Sisi Wu, Haoming Tian
    Molecular Medicine Reports.2019;[Epub]     CrossRef
  • Liraglutide alters hepatic metabolism in high-fat fed obese mice: A bioinformatic prediction and functional analysis
    Isabelle Arruda Barbosa, Eloá Mangabeira Santos, Alanna Fernandes Paraíso, Pablo Vinicyus Ferreira Chagas, Luís Paulo Oliveira, João Marcus Oliveira Andrade, Lucyana Conceição Farias, Bruna Mara Aparecida de Carvalho, Alfredo Maurício Batista de Paula, An
    Meta Gene.2019; 20: 100553.     CrossRef
  • Dipeptidyl peptidase‐4 inhibitors and aerobic exercise synergistically protect against liver injury in ovariectomized rats
    Nagat Younan, Samah Elattar, Mira Farouk, Laila Rashed, Suzanne Estaphan
    Physiological Reports.2019;[Epub]     CrossRef
  • Microbial Metabolites Determine Host Health and the Status of Some Diseases
    Panida Sittipo, Jae-won Shim, Yun Lee
    International Journal of Molecular Sciences.2019; 20(21): 5296.     CrossRef
  • Compound K attenuates glucose intolerance and hepatic steatosis through AMPK-dependent pathways in type 2 diabetic OLETF rats
    Yoo-Cheol Hwang, Da-Hee Oh, Moon Chan Choi, Sang Yeoul Lee, Kyu-Jeong Ahn, Ho-Yeon Chung, Sung-Jig Lim, Sung Hyun Chung, In-Kyung Jeong
    The Korean Journal of Internal Medicine.2018; 33(2): 347.     CrossRef
  • Liraglutide attenuates partial warm ischemia-reperfusion injury in rat livers
    Ahmed A. Abdelsameea, Noha A.T. Abbas, Samar M. Abdel Raouf
    Naunyn-Schmiedeberg's Archives of Pharmacology.2017; 390(3): 311.     CrossRef
  • Natural alkaloid bouchardatine ameliorates metabolic disorders in high‐fat diet‐fed mice by stimulating the sirtuin 1/liver kinase B‐1/AMPK axis
    Yong Rao, Hong Yu, Lin Gao, Yu‐Ting Lu, Zhao Xu, Hong Liu, Lian‐Quan Gu, Ji‐Ming Ye, Zhi‐Shu Huang
    British Journal of Pharmacology.2017; 174(15): 2457.     CrossRef
  • Non-alcoholic fatty liver disease and dyslipidemia: An update
    Niki Katsiki, Dimitri P. Mikhailidis, Christos S. Mantzoros
    Metabolism.2016; 65(8): 1109.     CrossRef
  • Exendin-4 Inhibits Hepatic Lipogenesis by Increasing β-Catenin Signaling
    Mi Hae Seo, Jinmi Lee, Seok-Woo Hong, Eun-Jung Rhee, Se Eun Park, Cheol Young Park, Ki Won Oh, Sung Woo Park, Won-Young Lee, Catherine Mounier
    PLOS ONE.2016; 11(12): e0166913.     CrossRef
  • The Relationship between Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Measured by Controlled Attenuation Parameter
    Young Eun Chon, Kwang Joon Kim, Kyu Sik Jung, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Chae Yoon Chon, Jae Bock Chung, Kyeong Hye Park, Ji Cheol Bae, Kwang-Hyub Han
    Yonsei Medical Journal.2016; 57(4): 885.     CrossRef
  • The role of the gut microbiota in NAFLD
    Christopher Leung, Leni Rivera, John B. Furness, Peter W. Angus
    Nature Reviews Gastroenterology & Hepatology.2016; 13(7): 412.     CrossRef
  • Extrapancreatic effects of incretin hormones: evidence for weight‐independent changes in morphological aspects and oxidative status in insulin‐sensitive organs of the obese nondiabetic Zucker rat (ZFR)
    Ides M. Colin, Henri Colin, Ines Dufour, Charles‐Edouard Gielen, Marie‐Christine Many, Jean Saey, Bernard Knoops, Anne‐Catherine Gérard
    Physiological Reports.2016;[Epub]     CrossRef
  • A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence
    Jonathan Temple, Paul Cordero, Jiawei Li, Vi Nguyen, Jude Oben
    International Journal of Molecular Sciences.2016; 17(6): 947.     CrossRef
  • Extrapancreatic Effect of Glucagon like Peptide-1
    In-Kyung Jeong
    The Korean Journal of Medicine.2015; 89(4): 404.     CrossRef
  • Green Tea Extract Rich in Epigallocatechin-3-Gallate Prevents Fatty Liver by AMPK Activation via LKB1 in Mice Fed a High-Fat Diet
    Aline B. Santamarina, Juliana L. Oliveira, Fernanda P. Silva, June Carnier, Laís V. Mennitti, Aline A. Santana, Gabriel H. I. de Souza, Eliane B. Ribeiro, Cláudia M. Oller do Nascimento, Fábio S. Lira, Lila M. Oyama, Patricia Aspichueta
    PLOS ONE.2015; 10(11): e0141227.     CrossRef
  • Acarbose, lente carbohydrate, and prebiotics promote metabolic health and longevity by stimulating intestinal production of GLP-1
    Mark F McCarty, James J DiNicolantonio
    Open Heart.2015; 2(1): e000205.     CrossRef
  • The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease
    Huiting Gao, Zhigang Zeng, Han Zhang, Xiaoli Zhou, Lichang Guan, Weiping Deng, Lishu Xu
    Biological & Pharmaceutical Bulletin.2015; 38(5): 694.     CrossRef
  • Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance
    Sri Harsha Tella, Marc S. Rendell
    Therapeutic Advances in Endocrinology and Metabolism.2015; 6(3): 109.     CrossRef
  • Gut Microbiota: Association with NAFLD and Metabolic Disturbances
    E. Lau, D. Carvalho, P. Freitas
    BioMed Research International.2015; 2015: 1.     CrossRef
  • Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes
    James J DiNicolantonio, Jaikrit Bhutani, James H O'Keefe
    Open Heart.2015; 2(1): e000327.     CrossRef
  • Nonalcoholic fatty liver disease and bariatric surgery in adolescents
    AiXuan Holterman, Juan Gurria, Smita Tanpure, Nerina DiSomma
    Seminars in Pediatric Surgery.2014; 23(1): 49.     CrossRef
  • Pediatric non-alcoholic fatty liver disease: New insights and future directions
    Pierluigi Marzuillo
    World Journal of Hepatology.2014; 6(4): 217.     CrossRef
  • 4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine—recommendations for facing obesity, fatty liver and fibrosis epidemics
    Francesca Maria Trovato, Daniela Catalano, Giuseppe Musumeci, Guglielmo M Trovato
    EPMA Journal.2014;[Epub]     CrossRef
  • The Role of Medications for the Management of Patients with NAFLD
    Natalia Mazzella, Laura M. Ricciardi, Arianna Mazzotti, Giulio Marchesini
    Clinics in Liver Disease.2014; 18(1): 73.     CrossRef
  • Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non‐alcoholic steatohepatitis
    A. Alisi, G. Bedogni, G. Baviera, V. Giorgio, E. Porro, C. Paris, P. Giammaria, L. Reali, F. Anania, V. Nobili
    Alimentary Pharmacology & Therapeutics.2014; 39(11): 1276.     CrossRef
  • The cardiometabolic benefits of glycine: Is glycine an ‘antidote’ to dietary fructose?
    Mark F McCarty, James J DiNicolantonio
    Open Heart.2014; 1(1): e000103.     CrossRef
  • Pediatric non-alcoholic fatty liver disease: an increasing public health issue
    S. Berardis, E. Sokal
    European Journal of Pediatrics.2014; 173(2): 131.     CrossRef
  • Glucagon‐like peptide‐1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease
    H. Kahal, G. Abouda, A. S. Rigby, A. M. Coady, E. S. Kilpatrick, S. L. Atkin
    Clinical Endocrinology.2014; 81(4): 523.     CrossRef
  • Comparative analysis of plasma metabolomics response to metabolic challenge tests in healthy subjects and influence of the FTO obesity risk allele
    Simone Wahl, Susanne Krug, Cornelia Then, Anna Kirchhofer, Gabi Kastenmüller, Tina Brand, Thomas Skurk, Melina Claussnitzer, Cornelia Huth, Margit Heier, Christa Meisinger, Annette Peters, Barbara Thorand, Christian Gieger, Cornelia Prehn, Werner Römisch-
    Metabolomics.2014; 10(3): 386.     CrossRef
  • Role of thiazolidinediones, insulin sensitizers, in non‐alcoholic fatty liver disease
    Eugene Chang, Cheol‐Young Park, Sung Woo Park
    Journal of Diabetes Investigation.2013; 4(6): 517.     CrossRef
  • Therapeutic options in pediatric non alcoholic fatty liver disease: current status and future directions
    Pietro Vajro, Selvaggia Lenta, Claudio Pignata, Mariacarolina Salerno, Roberta D’Aniello, Ida De Micco, Giulia Paolella, Giancarlo Parenti
    Italian Journal of Pediatrics.2012; 38(1): 55.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer